Previews only
The UK's chief scientific adviser has a £600,000 shareholding in a drugs giant contracted to develop a Covid-19 vaccine for the Government, prompting claims of a potential conflict of interest. Sir Patrick Vallance, who also chairs the Government's expert advisory panel on vaccines, holds a deferred bonus of 43,111 shares in GlaxoSmithKline (GSK) worth £600,000 from his time as president of the multinational drug company, The Telegraph can reveal.
is only available to registered users. Visit the login page if you have an account. Otherwise visit the registration page to create one.